Your browser doesn't support javascript.
loading
Lisinopril: dose-peak effect relationship in essential hypertension.
Cirillo, V J; Gomez, H J; Salonen, J; Salonen, R; Rissanen, V; Bolognese, J A; Nyberg, R; Kristianson, K.
Afiliação
  • Cirillo VJ; Department of Cardiovascular Clinical Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065-0914.
Br J Clin Pharmacol ; 25(5): 533-8, 1988 May.
Article em En | MEDLINE | ID: mdl-2841960
ABSTRACT
1. The dose-peak effect relationship of lisinopril was evaluated in a double-blind, parallel study in 83 patients with mild to moderate essential hypertension (supine diastolic blood pressure = 95-115 mm Hg). 2. After a 4 week placebo washout, patients were randomly assigned to one of four treatments lisinopril 2.5, 10, 20 or 80 mg day-1 for 1 week. 3. Lisinopril 10 and 20 mg day-1 produced similar peak antihypertensive effects which were greater than that produced by 2.5 mg day-1, but less than that of 80 mg day-1. If the incidence of first-dose symptomatic hypotension is related to the peak effect, then an initial lisinopril dose of 20 mg should not pose any greater risk than a 10 mg dose. 4. The magnitude of antihypertensive response at 24 h postdrug appeared to be dose related across the 2.5 to 80 mg day-1 range.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Enalapril / Hipertensão Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 1988 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Enalapril / Hipertensão Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 1988 Tipo de documento: Article